TENX
NASDAQTenax Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks410%
2026-03-012026-08-23
Mix1990d
- SEC Filings7(37%)
- Analyst5(26%)
- Other3(16%)
- Insider3(16%)
- Earnings1(5%)
Latest news
25 items- INSIDERLarge owner Adar1 Capital Management, Llc bought $1,814,147 worth of shares (1,025,867 units at $1.77) (SEC Form 4)4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- INSIDERNew insider Adar1 Capital Management, Llc claimed ownership of 3,827,951 shares (SEC Form 3)3 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- ANALYSTTenax Therapeutics downgraded by Chardan Capital Markets with a new price targetChardan Capital Markets downgraded Tenax Therapeutics from Buy to Neutral and set a new price target of $5.00
- ANALYSTTenax Therapeutics downgraded by Evercore ISI with a new price targetEvercore ISI downgraded Tenax Therapeutics from Outperform to In-line and set a new price target of $5.00
- SECSEC Form 8-K filed by Tenax Therapeutics Inc.8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- PRTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEFTNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo In prespecified exploratory analyses in the overall trial population, treatment with TNX-103 resulted in a 49% greater reduction in NT-proBNP compared to placebo (nominal p<0.0001) and a reduction of 3.5 mmHg in right ventricular systolic pressure compared to placebo (nominal p=0.0045) In a prespecified analysis, patients with a baseline 6-minute walk distance below the trial median of 333 meters showed a 26.3-meter improvement compared to placebo (95% CI 6.0, 46.7; nominal p=0.0112) Company to hold conference call and webcast today at 8:00 a.m. ET CHAPEL HILL, N.
- SECSEC Form 10-Q filed by Tenax Therapeutics Inc.10-Q - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECTenax Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- PRTenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateCompany expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company") today reported financial results for the quarter ended June 30, 2026 and provided an update on its corporate progress. "We are approaching an exciting moment, one for which we have been preparing since we began developing a therapy uniquely suited for PH-HFpEF. As we announced at the start of July, we expect to have topline data from the LEVEL clinical trial in August," said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. "In parall
- ANALYSTCanaccord Genuity initiated coverage on Tenax Therapeutics with a new price targetCanaccord Genuity initiated coverage of Tenax Therapeutics with a rating of Buy and set a new price target of $35.00
- ANALYSTEvercore ISI initiated coverage on Tenax Therapeutics with a new price targetEvercore ISI initiated coverage of Tenax Therapeutics with a rating of Outperform and set a new price target of $39.00
- INSIDERCEO Giordano Christopher Thomas exercised 8,719 shares at a strike of $5.88, increasing direct ownership by 335% to 11,324 units (SEC Form 4)4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- PRTenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it awarded inducement option awards on July 1, 2026 as material inducements to the employment of three non-executive individuals newly hired by the Company in various accounting, clinical operations, and CMC/product development roles. The employees received or will receive, in the aggregate, non-qualified stock options to purchase 160,000 shares of the Company's common stock with an exercise price equal to the clo
- SECSEC Form 8-K filed by Tenax Therapeutics Inc.8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- PRTenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company") announced today that results from the Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026, being held August 28-31 in Munich, Germany. In anticipation of potentially receiving topline results from the LEVEL clinical trial in time for presentation at ESC, an abstract was recently submitted. The Company now expects
- SECSEC Form 8-K filed by Tenax Therapeutics Inc.8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECSEC Form 8-K filed by Tenax Therapeutics Inc.8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- ANALYSTChardan Capital Markets initiated coverage on Tenax Therapeutics with a new price targetChardan Capital Markets initiated coverage of Tenax Therapeutics with a rating of Buy and set a new price target of $27.00
- SECSEC Form 8-K filed by Tenax Therapeutics Inc.8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tenax Therapeutics Inc.SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tenax Therapeutics Inc.SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)
- INSIDERChief Financial Officer Staab Thomas R Ii was granted 10,000 shares (SEC Form 4)4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- INSIDERNew insider Staab Thomas R Ii claimed no ownership of stock in the company (SEC Form 3)3 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)
- SECSEC Form S-8 filed by Tenax Therapeutics Inc.S-8 - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
- SECSEC Form 10-Q filed by Tenax Therapeutics Inc.10-Q - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
TENX FAQ
6 questionsWhat does Tenax Therapeutics Inc. do?
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax...Where does TENX stock trade?
Tenax Therapeutics Inc. (TENX) is listed on NASDAQ.What sector and industry is TENX in?
Tenax Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TENX?
Tenax Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Chardan Capital Markets: Neutral with a $500.00 price target on 2026-08-11.What companies are similar to TENX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TENX side-by-side with any of them on Quantisnow.How can I track TENX on Quantisnow?
Quantisnow aggregates Tenax Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TENX to receive live email and push alerts on every new disclosure.